Expensive blood safety initiatives may offer less benefit than we think

Mads Kamper-Jørgensen, Henrik Hjalgrim, Gustaf Edgren, Kjell Titlestad, Henrik Ullum, Agneta Shanwell, Marie Reilly, Mads Melbye, Olof Nyrén, Klaus Rostgaard

Research output: Contribution to journalJournal articleResearchpeer-review

8 Citations (Scopus)

Abstract

Various blood safety initiatives have ensured a historically low risk of infection transmission through blood transfusion. Although further prevention of infection transmission is possible through, for example, nucleic acid testing and future introduction of pathogen inactivation, such initiatives are very costly in relation to the benefit they offer. Although estimation of the cost-effectiveness requires detailed information about the survival of transfusion recipients, previous cost-effectiveness analyses have relied on incorrect survival assumptions.
Original languageEnglish
JournalTransfusion
Volume50
Issue number1
Pages (from-to)240-2
Number of pages3
ISSN0041-1132
DOIs
Publication statusPublished - Jan 2010

Keywords

  • Blood Banks
  • Blood Transfusion
  • Cost-Benefit Analysis
  • Follow-Up Studies
  • Humans
  • Infection
  • Infection Control
  • Quality of Health Care
  • Quality-Adjusted Life Years
  • Risk Factors
  • Scandinavia
  • Survival Analysis

Cite this